AR048532A1 - Derivados de 4 - alquil y 4- alcanol- piperidina sustituidos y su uso como antagonistas de neuroquininas - Google Patents
Derivados de 4 - alquil y 4- alcanol- piperidina sustituidos y su uso como antagonistas de neuroquininasInfo
- Publication number
- AR048532A1 AR048532A1 ARP050101376A ARP050101376A AR048532A1 AR 048532 A1 AR048532 A1 AR 048532A1 AR P050101376 A ARP050101376 A AR P050101376A AR P050101376 A ARP050101376 A AR P050101376A AR 048532 A1 AR048532 A1 AR 048532A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- radical
- group
- amino
- integer equal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
La presente comprende sus sales de adicion de base o ácido farmacéuticamente aceptables; sus formas estereoquímicamente isomeras; su forma de N-oxido; y sus profármacos. Reivindicacion 1: Un compuesto de acuerdo con la formula general (1), sus sales de adicion de ácido o base farmacéuticamente aceptables, sus formas estereoquímicamente isomeras, su forma N-oxido y sus profármacos, en donde: n es un entero igual a 0, 1 o 2; m es un entero igual a 1 o 2, siempre que si m es 2 entonces n es 1; cada R1, de manera independiente entre sí, se selecciona del grupo de Ar1, Ar1-alquilo y di(Ar1)-alquilo; R4 se selecciona del grupo de hidrogeno, hidroxi y alquiloxi; Z es un radical bivalente -(CH2)r-, en donde r es un entero igual a 1, 2, 3, 4 o 5, y en donde un radical -CH2- está opcionalmente reemplazado por un radical >C(=O); o R4 y Z se toman juntos para formar un radical trivalente =CH-(CH2)r-1-, en donde r es un entero igual a 2, 3, 4, o 5, y en donde un radical -CH2- está opcionalmente reemplazado por un radical >C=O; p es un entero igual a 1 o 2; Q es O o NR3; X es un enlace covalente o un radical bivalente de formula -O-, -S-, o -NR3-; cada R3, de manera independientemente entre sí, es hidrogeno o alquilo; R2 es alquilo, Ar2, Ar2-alquilo, Het1 o Het1-alquilo; q es un entero igual a 0 o 1; j es un entero igual a 0, 1 o 2; k es un entero igual a 0, 1 o 2; Y es un enlace covalente o un radical bivalente de formula >C(=O) o -SO2-; cada Alk representa, de manera independiente entre sí, un enlace covalente; un radical hidrocarburo bivalente recto o ramificado, saturado o insaturado C1-6; o un radical hidrocarburo cíclico saturado o insaturado C3-6; cada radical está opcionalmente sustituido en uno o más átomos de carbono con uno o más radicales alquilo, fenilo, halo, ciano, hidroxi, formilo y amino; L se selecciona del grupo de hidrogeno, alquilo, alquiloxi, Ar3-oxi, alquiloxicarbonilo, mono- y di(alquil)amino, mono- y di(Ar3)amino, mono- y di(alquiloxicarbonil)amino, Ar3, Ar3-carbonilo, Het2, Het2-carbonilo; Ar1 es fenilo, opcionalmente sustituido con 1, 2 o 3 sustituyentes en donde cada uno, de manera independiente entre sí, se selecciona del grupo de halo, alquilo, ciano, aminocarbonilo y alquiloxi; Ar2 es naftalenilo o fenilo, cada uno opcionalmente sustituido con 1, 2 o 3 sustituyentes en donde cada sustituyente, de manera independiente entre sí, seleccionado del grupo de halo, nitro, amino, mono- y di(alquil)amino, ciano, alquilo, hidroxi, alquiloxi, carboxilo, alquiloxicarbonilo, aminocarbonilo, y mono- y di(alquil)aminocarbonilo; Ar3 es naftalenilo o fenilo, opcionalmente sustituido con 1, 2 o 3 sustituyentes en donde cada sustituyente independiente entre sí, se selecciona del grupo de alquiloxi, alquilo, halo, hidroxi, piridinilo, morfolinilo, pirrolidinilo, imidazo[1,2-alfa]piridinilo, morfolinilcarbonilo, pirrolidinilcarbonilo, amino y ciano; Het1 es un radical heterocíclico monocíclico seleccionado del grupo de pirrolilo, pirazolilo, imidazolilo, furanilo, tienilo, oxazolilo, isoxazolilo, tiazolilo, tiadiazolilo, isotiazolilo, piridinilo, pirimidinilo, pirazinilo, y piridazinilo; o un radical heterocíclico bicíclico seleccionado del grupo de quinolinilo, quinoxalinilo, indolilo, bencimidazolilo, benzoxazolilo, benzisoxazolilo, benzotiazolilo, benzisotiazolilo, benzofuranilo y benzotienilo; cada radical heterocíclico puede estar opcionalmente sustituido en cualquiera átomo con uno o más radicales seleccionados del grupo de halo y alquilo; Het2 es un radical heterocíclico monocíclico seleccionado del grupo de pirrolidinilo, dioxolilo, imidazolidinilo, pirrazolidinilo, piperidinilo, morfolinilo, ditianilo, tiomorfolinilo, piperazinilo, imidazolidinilo, tetrahidrofuranilo, 2H-pirrolilo, pirrolinilo, imidazolinilo, pirrazolinilo, pirrolilo, imidazolilo, pirazolilo, triazolilo, furanilo, tienilo, oxazolilo, isoxazolilo, tiazolilo, tiadiazolilo, isotiazolilo, piridinilo, pirimidinilo, pirazinilo, piridazinilo, triazinilo; o un radical heterocíclico bicíclico seleccionado del grupo de benzopiperidinilo, quinolinilo, quinoxalinilo, indolilo, isoindolilo, cromenilo, bencimidazolilo, imidazo[1,2-alfa]piridinilo, benzoxazolilo, benzisoxazolilo, benzotiazolilo, benzisotiazolilo, benzofuranilo, y benzotienilo; cada radical heterocíclico puede estar opcionalmente sustituido en cualquier átomo con uno o más radicales seleccionados del grupo de Ar1, Ar1alquilo, halo, hidroxi, alquilo, piperidinilo, pirrolilo, tienilo, oxo, alquiloxi, alquiloxialquilo y alquiloxicarbonilo; Alquilo es un radical hidrocarburo saturado, recto o ramificado C1-6; o un radical hidrocarburo saturado cíclico C3-6; opcionalmente sustituido en uno o más átomos de carbono con uno o más radicales seleccionados del grupo de fenilo, halo, ciano, oxo, hidroxi, formilo y amino.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04101467 | 2004-04-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR048532A1 true AR048532A1 (es) | 2006-05-03 |
Family
ID=34928945
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050101376A AR048532A1 (es) | 2004-04-08 | 2005-04-07 | Derivados de 4 - alquil y 4- alcanol- piperidina sustituidos y su uso como antagonistas de neuroquininas |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20070213346A1 (es) |
| EP (1) | EP1737838B1 (es) |
| JP (1) | JP2007532516A (es) |
| KR (1) | KR20070007347A (es) |
| CN (1) | CN1938291B (es) |
| AR (1) | AR048532A1 (es) |
| AT (1) | ATE396185T1 (es) |
| AU (1) | AU2005231986B2 (es) |
| BR (1) | BRPI0509720A (es) |
| CA (1) | CA2561967A1 (es) |
| DE (1) | DE602005007002D1 (es) |
| EA (1) | EA010312B1 (es) |
| ES (1) | ES2307169T3 (es) |
| IL (1) | IL178461A0 (es) |
| JO (1) | JO2525B1 (es) |
| MX (1) | MXPA06011683A (es) |
| MY (1) | MY142773A (es) |
| NO (1) | NO20065022L (es) |
| NZ (1) | NZ550098A (es) |
| PA (1) | PA8628901A1 (es) |
| TW (1) | TWI358298B (es) |
| WO (1) | WO2005097774A1 (es) |
| ZA (1) | ZA200608356B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7659275B2 (en) * | 2005-02-23 | 2010-02-09 | Schering Corporation | Piperidinyl piperazine derivatives useful as inhibitors of chemokine receptors |
| TWI385169B (zh) | 2005-10-31 | 2013-02-11 | Eisai R&D Man Co Ltd | 經雜環取代之吡啶衍生物及含有彼之抗真菌劑 |
| TW200841879A (en) | 2007-04-27 | 2008-11-01 | Eisai R&D Man Co Ltd | Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same |
| US8513287B2 (en) | 2007-12-27 | 2013-08-20 | Eisai R&D Management Co., Ltd. | Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same |
| ES2422718T3 (es) * | 2009-04-02 | 2013-09-13 | Merck Patent Gmbh | Derivados de piperidina y piperazina como inhibidores de la autotaxina |
| CN102428069B (zh) | 2009-04-02 | 2014-04-02 | 盐野义制药株式会社 | 丙烯酰胺化合物及其用途 |
| JP5806672B2 (ja) * | 2009-10-30 | 2015-11-10 | ドメイン・セラピューティクス | 新規オキシム誘導体及び代謝型グルタミン酸受容体のアロステリック調節因子としての利用 |
| KR101716099B1 (ko) * | 2013-09-12 | 2017-03-13 | 에프. 호프만-라 로슈 아게 | 인돌-카복스아마이드 유도체 |
| RU2743206C2 (ru) | 2015-05-18 | 2021-02-16 | Кэнди Терапьютикс Лимитед | Двойные антагонисты рецептора нейрокинин-1/нейрокинин-3 для лечения заболеваний, зависимых от половых гормонов |
| AU2019233606A1 (en) | 2018-03-14 | 2020-09-17 | KaNDy Therapeutics Limited | Novel pharmaceutical formulation comprising dual NK-1/NK-3 receptor antagonists |
| ES2963356T3 (es) * | 2019-06-12 | 2024-03-26 | Nouryon Chemicals Int Bv | Método para aislar ácido carboxílico a partir de una corriente lateral acuosa |
| JP7336541B2 (ja) | 2019-06-12 | 2023-08-31 | ヌーリオン ケミカルズ インターナショナル ベスローテン フェノーツハップ | 過酸化ジアシルを生成するためのプロセス |
| HUE063796T2 (hu) | 2019-06-12 | 2024-01-28 | Nouryon Chemicals Int Bv | Eljárás diacil-peroxidok elõállítására |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ321575A (en) * | 1995-10-30 | 1999-05-28 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives |
| TW382017B (en) * | 1995-12-27 | 2000-02-11 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4-(fused imidazole)-piperidine derivatives |
| GB0025354D0 (en) * | 2000-10-17 | 2000-11-29 | Glaxo Group Ltd | Chemical compounds |
| US6642226B2 (en) * | 2001-02-06 | 2003-11-04 | Hoffman-La Roche Inc. | Substituted phenyl-piperidine methanone compounds |
| US7514424B2 (en) * | 2002-12-23 | 2009-04-07 | Janssen Pharmaceutica N.V. | Substituted 4-(4-piperidin-4-yl-piperazin-1-yl)-azepane derivatives and their use as neurokinin antagonists |
-
2005
- 2005-03-22 JO JO200534A patent/JO2525B1/en active
- 2005-04-04 AT AT05729797T patent/ATE396185T1/de active
- 2005-04-04 KR KR1020067021935A patent/KR20070007347A/ko not_active Application Discontinuation
- 2005-04-04 ES ES05729797T patent/ES2307169T3/es active Active
- 2005-04-04 AU AU2005231986A patent/AU2005231986B2/en not_active Ceased
- 2005-04-04 JP JP2007506775A patent/JP2007532516A/ja not_active Ceased
- 2005-04-04 CA CA002561967A patent/CA2561967A1/en not_active Abandoned
- 2005-04-04 NZ NZ550098A patent/NZ550098A/en unknown
- 2005-04-04 DE DE602005007002T patent/DE602005007002D1/de active Active
- 2005-04-04 WO PCT/EP2005/051509 patent/WO2005097774A1/en active IP Right Grant
- 2005-04-04 BR BRPI0509720-7A patent/BRPI0509720A/pt not_active IP Right Cessation
- 2005-04-04 US US11/547,868 patent/US20070213346A1/en not_active Abandoned
- 2005-04-04 EA EA200601880A patent/EA010312B1/ru not_active IP Right Cessation
- 2005-04-04 MX MXPA06011683A patent/MXPA06011683A/es active IP Right Grant
- 2005-04-04 EP EP05729797A patent/EP1737838B1/en active Active
- 2005-04-04 CN CN2005800108231A patent/CN1938291B/zh not_active Expired - Fee Related
- 2005-04-05 PA PA20058628901A patent/PA8628901A1/es unknown
- 2005-04-06 MY MYPI20051549A patent/MY142773A/en unknown
- 2005-04-07 AR ARP050101376A patent/AR048532A1/es not_active Application Discontinuation
- 2005-04-07 TW TW094110941A patent/TWI358298B/zh not_active IP Right Cessation
-
2006
- 2006-10-05 IL IL178461A patent/IL178461A0/en unknown
- 2006-10-06 ZA ZA200608356A patent/ZA200608356B/en unknown
- 2006-11-03 NO NO20065022A patent/NO20065022L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2561967A1 (en) | 2005-10-20 |
| JP2007532516A (ja) | 2007-11-15 |
| DE602005007002D1 (de) | 2008-07-03 |
| TW200603797A (en) | 2006-02-01 |
| CN1938291B (zh) | 2011-11-16 |
| BRPI0509720A (pt) | 2007-09-25 |
| AU2005231986A1 (en) | 2005-10-20 |
| CN1938291A (zh) | 2007-03-28 |
| KR20070007347A (ko) | 2007-01-15 |
| US20070213346A1 (en) | 2007-09-13 |
| EP1737838A1 (en) | 2007-01-03 |
| PA8628901A1 (es) | 2006-09-08 |
| MXPA06011683A (es) | 2006-12-14 |
| ATE396185T1 (de) | 2008-06-15 |
| ES2307169T3 (es) | 2008-11-16 |
| NZ550098A (en) | 2009-10-30 |
| IL178461A0 (en) | 2007-02-11 |
| EA200601880A1 (ru) | 2007-02-27 |
| WO2005097774A1 (en) | 2005-10-20 |
| EP1737838B1 (en) | 2008-05-21 |
| AU2005231986B2 (en) | 2011-02-24 |
| MY142773A (en) | 2010-12-31 |
| EA010312B1 (ru) | 2008-08-29 |
| JO2525B1 (en) | 2010-03-17 |
| TWI358298B (en) | 2012-02-21 |
| NO20065022L (no) | 2006-11-03 |
| ZA200608356B (en) | 2008-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR048532A1 (es) | Derivados de 4 - alquil y 4- alcanol- piperidina sustituidos y su uso como antagonistas de neuroquininas | |
| AR041545A1 (es) | Derivados sustituidos de 1,4-di-piperidin-4 il-piperazina y su uso como antagonistas de neuroquininas | |
| AR048522A1 (es) | Derivados sustituidos de diaza-espiro-(5.5)-undecano y su uso como antagonistas de neuroquininas | |
| AR048521A1 (es) | Derivados sustituidos de diaza-espiro-(4.5)-decano y su uso como antagonistas de neuroquininas | |
| AR035991A1 (es) | Derivados de benzimidazoles e imidazopiridinas, un procedimiento para su preparacion, composiciones farmaceuticas, un procedimiento para su preparacion, y un medicamento utiles como inhibidores de la replicacion del virus sincitial respiratorio | |
| AR024495A1 (es) | Inhibidores de la replicacion del virus sincitial respiratorio. | |
| AR071763A1 (es) | Pirazoles trisustituidos, composiciones farmaceuticas que los contienen, y usos de los mismos en el tratamiento de trastornos neurologicos y psiquiatricos | |
| AR040475A1 (es) | Espiropiperidinas o espiropirrolidinas triciclicas | |
| EA200970493A1 (ru) | Макроциклические ингибиторы вируса гепатита с | |
| AR080314A1 (es) | Derivado de 1,3,4,8-tetrahidro-2h-pirido (1,2-a) pirazina y su uso como inhibidor de la hiv integrasa | |
| AR081649A1 (es) | Compuestos heteroarilo nitrogenados | |
| AR036093A1 (es) | Compuestos derivados de tiazolidinilo, pirrolidinilo, oxazolidinilo, piperidilo, morfolinilo y tiomorfolinilo, su uso, composiciones farmaceuticas que los comprenden, y compuestos intermediarios | |
| PA8783601A1 (es) | Derivados de piperidina/piperazina | |
| AR056215A1 (es) | Derivados de indol como inhibidores de la proteina activadora de 5-lipoxigenasa (flap), composiciones farmaceuticas que los comprenden y su uso en el tratamiento de trastornos respiratorios e inflamatorios | |
| MX357131B (es) | Composicion para el control de plagas que incluye un derivado de iminopiridina novedoso. | |
| AR076579A1 (es) | Espironucleosidos uracilicos oxetanicos, composiciones farmaceuticas que los contienen y uso de los mismos como inhibidores del virus de la hepatitis c (vhc). | |
| WO2015049517A3 (en) | Animal models and therapeutic molecules | |
| BR112014006840A2 (pt) | derivados de pirrolopirimidina e purina | |
| CY1110399T1 (el) | Ρυθμιστες της τετραϋδροπυρανυλο κυκλοπεντυλο τετραϋδροπυριδοπυριδινης για την ενεργοτητα των υποδοχεων των χημειοκινων | |
| AR074596A1 (es) | Derivados de (3-oxo) piridazin-4-ilurea | |
| UY29047A1 (es) | Derivados de sulfonamidas, su preparación y su aplicación en terapéutica | |
| WO2006087476A3 (fr) | Derives de 1,5-diarylpyrrole, leur preparation et leur application en therapeutique | |
| AR087182A1 (es) | DERIVADOS DE INDOL SUSTITUIDOS COMO MODULADORES DE g SECRETASA | |
| AR074504A1 (es) | Nucleotidos uracil ciclopropilicos | |
| GT200600478A (es) | Compuestos utiles en terapia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |